I agree, however I'm not sure if Leo's top priority right now is to chase institutional funding. It doesn't appear (to me) that funding is necessarily a huge discussion right now. They seem to be doing just fine without needing a huge infusion of cash. I'm sure when the trials are in a more mature state, uplisting will be bigger discussion point but I just don't see it right now.